Researchers develop a new class of covalent inhibitor for a protein involved in brain diseases Blog Post

An article published in Cell Chemical Biology by scientists at the Institute for Research in Biomedicine (IRB Barcelona) in Barcelona Science Park (PCB) describes a new class of prolyl oligopeptidase (POP) inhibitors. Found mostly in the brain, POP protein has emerged as an “attractive·” therapeutic target for the treatment of several cognitive and neurodegenerative disorders, such as Parkinson’s disease and schizophrenia.The work was done in collaboration with the biotech Iproteos, based in PCB and scientists at the University of Glasgow (Scotland, UK) and the Utrecht Institute for Pharmaceutical Sciences (the Netherlands). The study has also involved the Nuclear Magnetic Resonance Laboratory (LRB) –wich is part of CCiTUB and it’s located in the Cluster building of the Park– and the Barcelona Supercomputing Center (BSC).

 

A new study reveals effectiveness of a cognitive enhancer for schizophrenia treatment Blog Post

Researchers from the biotech company Iproteos and the Institute for Research in Biomedicine of Barcelona (IRB Barcelona), member of the Barcelona Institute of Science and Technology (BIST) –based at the Barcelona Science Park–  in collaboration with scientists from the Neuropsychopharmacology Research Group –belonging to the University of Basque Country /Universidad del País Vasco (UPV/EHU) and to the Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM)– have published an article at European Neuropsychopharmacology, where the new procognitive drug efficacy has been demonstrated for schizophrenia treatment.

 

Gate2Brain of IRB Barcelona is one of the projects supported by the RecerCaixa Programme Blog Post

The project “Gate2Brain, peptide shuttles for protein replacement therapy in Friedreich’s ataxia“, led by Ernest Giralt, head of the Peptides and Proteins Lab at the Institute for Research in Biomedicine (IRB Barcelona) –based in the PCB– and full professor of the University of Barcelona, and by Javier Díaz Nido, at the Centro de Biología Molecular Severo Ochoa (CBMSO), has been awarded funding from the RecerCaixa Programme—an initiative of the Obra Social “la Caixa” with the collaboration of the Associació Catalana d’Universitats Públiques(ACUP).